Clinical Trial: A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies

U.S., Aug. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07784309) titled 'A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies' on Aug. 05.

Brief Summary: This study is a single-arm, open-label, non-randomized clinical trial aimed at evaluating the safety, tolerability and preliminary efficacy of HY035 cell injection in the treatment of patients with CD7-positive relapsed or refractory hematologic malignancies.

Study Start Date: Aug. 15

Study Type: INTERVENTIONAL

Condition: Acute T Cell Lymphoblastic Leukemia Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory Acute Myeloid Leukemia (AML) T Cell Lymphoma...